Back to results
US 2025/0060367 A1Published application
Methods and compositions for synthetic biomarkers
AssigneeEARLI Inc.
InventorsDavid SUHY, Paul ESCARPE, Cyriac ROEDING, Justin LIN, Alex HARWIG, Shireen RUDINA, Leland Harrison HARTWELL
Life of this patent
Estimating the term…
Abstract
The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.
Claims30
A method for treating a subject having a cancer or at risk of having said cancer, comprising:
- administering a genetic construct comprising an activatable molecule operably linked to a promoter of a gene overexpressed in a tumor cell versus a normal tissue or functional fragments of the promoter to said subject;
- wherein said activatable molecule is configured to be convert to a therapeutic molecule by an enzyme expressed by a tissue associated with said disease.
A method, comprising:
- (a) introducing to a subject suspected of having a lung, liver, ovarian, breast, muscle, bladder, colorectal, kidney, stomach, uterus, skin, or bone cancer via intravenous administration a plurality of DNA molecules, wherein:
- said plurality of DNA molecules comprises a plurality of different promoters comprising a family with sequence similarity 111 member B (FAM111B) promoter, an anterior gradient 2 protein disulphide isomerase family member (AGR2) promoter, a cystatin SN (CST1) promoter, a centrosomal protein 55 (CEP55) promoter, a CEA cell adhesion molecule 5 (CEACAM5) promoter, or a kinesin family member 20A (KIF20A) promoter, or functional fragments thereof operably linked to genes encoding reporter proteins, wherein said DNA molecules are selected from the group consisting of nanoplasmids and linear double-stranded DNA molecules;
- and
- (b) detecting said reporter proteins from or in said subject.
1 more element
(canceled)
(canceled)
Dependencies are inferred from the claim text.